DUBLIN, IRELAND — March 21, 2001 — The U.S. Food and Drug Administration has granted marketing approval of Elan Corporation, plc's new drug application for Avinza (morphine sulfate extended-release) capsules for the once-daily treatment of chronic, moderate-to-severe pain in patients who require continuous, around-the-clock therapy for an extended period of time, Elan announced today.
Avinza (formerly Morphelan) was developed by Elan Corporation, ("Elan"), which licensed the U.S. and Canadian marketing rights to Ligand Pharmaceuticals Inc. (Nasdaq: LGND) in 1998. Elan retains marketing rights for the rest of the world and regulatory filings are pending in major territories. The product will be manufactured by Elan in the United States and is expected to be launched in the second quarter of 2002.
"Avinza represents a major technical achievement for Elan and a medical advance in the management of chronic pain," said Donal J. Geaney, Chairman and Chief Executive Officer of Elan. "Using our proprietary controlled release technology (SODAS®), we have engineered a morphine capsule product, which gives patients protection from moderate to severe pain over a 24-hour period. In safety and effectiveness trials conducted by Elan, Avinza, given once daily, provided effective 24-hour pain relief. Avinza will provide an important therapeutic option for many patients who live with the pain …
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!